Company Filing History:
Years Active: 2024
Title: Pranav Bheamadu: Innovator in HIV Therapeutics
Introduction
Pranav Bheamadu is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of immunotherapy, particularly in the development of specific binding molecules for HIV treatment. His innovative work has the potential to improve therapeutic options for individuals infected with HIV.
Latest Patents
Pranav holds a patent for HIV specific binding molecules. This patent includes specific binding molecules, such as T cell receptors (TCRs), which bind the HLA-A*02 restricted peptide SLYNTVATL derived from the HIV Gag gene product, p17. The TCRs in this invention feature non-natural mutations within the alpha and/or beta variable domains compared to a native TCR. These specific binding molecules exhibit improved stability and yield while retaining advantageous properties. They are particularly useful in developing soluble immunotherapeutic reagents for treating HIV-infected individuals.
Career Highlights
Pranav is currently associated with Immunocore Limited, a company focused on innovative immunotherapy solutions. His work at Immunocore has positioned him as a key player in the advancement of treatments for viral infections, particularly HIV.
Collaborations
Pranav collaborates with talented individuals such as Marcin Dembek and Luis Filipe Da Silva Godinho. Their combined expertise contributes to the innovative research and development efforts at Immunocore.
Conclusion
Pranav Bheamadu's contributions to HIV therapeutics through his patented innovations highlight his role as a significant inventor in the field. His work promises to enhance treatment options for those affected by HIV, showcasing the importance of innovation in medical science.